Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Treatment-Resistant Depression in Patients with MDD

Among individuals with major depressive disorder (MDD), increased severity status is associated with incremental economic burden in patients with treatment-resistant depression (TRD), a new study found. Adult patients with TRD were identified who were stratified into mild, moderate, and severe cohorts based on the information in the last observed MDD ICD-9-CM code. Healthcare resource utilization (HRU) and costs of moderate to severe cohorts were compared to those of the mild cohort during 2-year follow-up after the first antidepressant claim. Among the findings:

  • Among 6,411 patients with TRD, 455 (7.1%) were identified as mild, 2,153 (33.6%) as moderate, and 1,455 (22.7%) as severe.
  • Increased severity status was associated with incremental burden in patients with TRD.
  • Inpatient admissions and outpatient visits were key drivers of incremental costs.

Citation:

Pilon D, Sheehan JJ, Szukis H, et al. Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression? [Published online ahead of print May 1, 2019]. J Affect Dis. doi:10.1016/j.jad.2019.04.100.